EP Patent

EP3907214A1 — Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use

Assigned to Dompe Farmaceutici SpA · Expires 2021-11-10 · 5y expired

What this patent protects

The present invention relates to a new co-crystal of Ketoprofen, Lysine and Gabapentin, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.

USPTO Abstract

The present invention relates to a new co-crystal of Ketoprofen, Lysine and Gabapentin, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.

Drugs covered by this patent

Patent Metadata

Patent number
EP3907214A1
Jurisdiction
EP
Classification
—
Expires
2021-11-10
Drug substance claim
No
Drug product claim
No
Assignee
Dompe Farmaceutici SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.